(Funded by the National Institutes of Health)
Researchers from Northwestern University and the University of California, San Diego, have developed new technology that could lead to the creation of a rapid point-of-care test for HIV infection. The technology uses a nanomechanical platform and tiny cantilevers to detect multiple HIV antigens at high sensitivity in a matter of minutes. Built into a solar-powered device, this technology could be taken to hard-to-reach parts of the world, where early detection remains a challenge to deliver fast interventions to vulnerable populations without waiting for lab results.

(Funded by the National Institutes of Health)
Researchers from the California NanoSystems Institute at the University of California, Los Angeles, have developed a sensor technology based on natural biochemical processes that can continuously and reliably measure multiple metabolites at once. The sensors are built onto electrodes made of tiny cylinders called single-wall carbon nanotubes. These electrodes use enzymes and other molecules to perform reactions that mirror the body’s metabolic processes. Depending on the target metabolite, the sensors either detect it directly or first convert it into a detectable form through a chain of intermediary enzymatic reactions. The team measured metabolites in sweat and saliva samples from patients receiving treatment for epilepsy and detected a gut bacteria-derived metabolite in the brain that could cause neurological disorders if it accumulates.

(Funded by the National Institutes of Health)
Researchers at the University of Pennsylvania have developed a new process that transports DNA into cells using lipid nanoparticles. Unlike messenger RNA (mRNA), DNA remains active in cells for months, or even years, and can be programmed to work only in targeted cells. But past attempts to use lipid nanoparticles to deliver DNA failed, because DNA can trigger severe immune reactions. The researchers discovered that by adding a natural anti-inflammatory molecule, called nitro-oleic acid, to the lipid nanoparticles, these immune reactions could be eliminated. With this advancement, treated cells produced intended therapeutic proteins for about six months from a single dose – much longer than the few hours seen with mRNA therapies.

(Funded by the National Institutes of Health)
Scientists from The Wistar Institute, the University of Pennsylvania, the Icahn School of Medicine at Mount Sinai, Saint Joseph’s University (Philadelphia, PA), and Inovio Pharmaceuticals (Plymouth Meeting, PA) have described a next-generation vaccination technology that combines plasmid DNA with a lipid nanoparticle delivery system. The team showed that these DNA lipid nanoparticles demonstrate a unique way of priming the immune system compared to mRNA and protein-in-adjuvant formulations and that these DNA lipid nanoparticles induced robust antibody and T-cell responses after a single dose. Importantly, these responses were durable, with memory responses in small animals persisting beyond a year after immunization.

(Funded by the National Institutes of Health)
Researchers from Oregon State University, Oregon Health & Science University, and international collaborators have developed magnetic nanoparticles in the shape of a cube sandwiched between two pyramids for the treatment of ovarian cancer. Made of iron oxide and doped with cobalt, the nanoparticles show exceptional heating efficiency when exposed to an alternating magnetic field. When the particles accumulate in cancerous tissue after intravenous injection, they are able to quickly rise to temperatures that weaken or destroy cancer cells. A cancer-targeting peptide helps the nanoparticles accumulate in the tumor, and because the nanoparticles’ heating efficiency is strong, the necessary concentration of nanoparticles can be achieved without a high dosage, limiting toxicity and side effects.